Sahar H. Mahmoud, Fatma R. Elfargani, Nagwa Mohamed, Fiaza A. Alhamdi
{"title":"二甲双胍治疗对2型糖尿病患者维生素B12水平的影响","authors":"Sahar H. Mahmoud, Fatma R. Elfargani, Nagwa Mohamed, Fiaza A. Alhamdi","doi":"10.1002/edm2.70049","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Diabetes mellitus (DM) is a serious health condition affecting people worldwide with a high prevalence rate. DM is classified according to its aetiology into type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM); several risk factors contribute to the development of T2DM, such as age, genetic predisposition and obesity. Metformin is a proven drug of choice, and it is used as a first-line treatment for patients with T2DM to improve their glycaemic levels. Vitamin B12 is an important water-soluble vitamin, and its deficiency can lead to megaloblastic anaemia.</p>\n </section>\n \n <section>\n \n <h3> Material and Methods</h3>\n \n <p>A Cross-sectional retrospective study was conducted on patients with T2DM in a Sedi Hussein diabetic polyclinic in Benghazi, Libya. The total sample was 381 patients: T1DM 15 (n), and T2DM 366 (n). T1DM was excluded from our results. Patients with T2DM were divided into two groups: the control group (not on metformin) consisted of 71 patients, and the group that received metformin (M group) consisted of 295 patients.</p>\n </section>\n \n <section>\n \n <h3> Aims of the Study</h3>\n \n <p>To assess serum vitamin B12 levels in patients with T2DM and evaluate the prevalence of vitamin B12 deficiency among those receiving metformin treatment.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The M group significantly decreased vitamin B12 serum levels by 443.56 mg/mL versus the control group of 541.33 pg/mL (<i>p</i> = 0.003). The prevalence of patients with vitamin B12 deficiency under the metformin treatment was 23.84%. There was no significant difference in correlation between serum vitamin B12 levels and both doses of metformin and the duration of diabetes mellitus.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Vitamin B12 was significantly decreased in patients with T2DM receiving metformin.</p>\n </section>\n </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 3","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70049","citationCount":"0","resultStr":"{\"title\":\"Impact of Metformin Therapy on Vitamin B12 Levels in Patients With Type 2 Diabetes Mellitus\",\"authors\":\"Sahar H. Mahmoud, Fatma R. Elfargani, Nagwa Mohamed, Fiaza A. Alhamdi\",\"doi\":\"10.1002/edm2.70049\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Introduction</h3>\\n \\n <p>Diabetes mellitus (DM) is a serious health condition affecting people worldwide with a high prevalence rate. DM is classified according to its aetiology into type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM); several risk factors contribute to the development of T2DM, such as age, genetic predisposition and obesity. Metformin is a proven drug of choice, and it is used as a first-line treatment for patients with T2DM to improve their glycaemic levels. Vitamin B12 is an important water-soluble vitamin, and its deficiency can lead to megaloblastic anaemia.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Material and Methods</h3>\\n \\n <p>A Cross-sectional retrospective study was conducted on patients with T2DM in a Sedi Hussein diabetic polyclinic in Benghazi, Libya. The total sample was 381 patients: T1DM 15 (n), and T2DM 366 (n). T1DM was excluded from our results. Patients with T2DM were divided into two groups: the control group (not on metformin) consisted of 71 patients, and the group that received metformin (M group) consisted of 295 patients.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Aims of the Study</h3>\\n \\n <p>To assess serum vitamin B12 levels in patients with T2DM and evaluate the prevalence of vitamin B12 deficiency among those receiving metformin treatment.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>The M group significantly decreased vitamin B12 serum levels by 443.56 mg/mL versus the control group of 541.33 pg/mL (<i>p</i> = 0.003). The prevalence of patients with vitamin B12 deficiency under the metformin treatment was 23.84%. There was no significant difference in correlation between serum vitamin B12 levels and both doses of metformin and the duration of diabetes mellitus.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Vitamin B12 was significantly decreased in patients with T2DM receiving metformin.</p>\\n </section>\\n </div>\",\"PeriodicalId\":36522,\"journal\":{\"name\":\"Endocrinology, Diabetes and Metabolism\",\"volume\":\"8 3\",\"pages\":\"\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-04-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70049\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Endocrinology, Diabetes and Metabolism\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/edm2.70049\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrinology, Diabetes and Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/edm2.70049","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Impact of Metformin Therapy on Vitamin B12 Levels in Patients With Type 2 Diabetes Mellitus
Introduction
Diabetes mellitus (DM) is a serious health condition affecting people worldwide with a high prevalence rate. DM is classified according to its aetiology into type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM); several risk factors contribute to the development of T2DM, such as age, genetic predisposition and obesity. Metformin is a proven drug of choice, and it is used as a first-line treatment for patients with T2DM to improve their glycaemic levels. Vitamin B12 is an important water-soluble vitamin, and its deficiency can lead to megaloblastic anaemia.
Material and Methods
A Cross-sectional retrospective study was conducted on patients with T2DM in a Sedi Hussein diabetic polyclinic in Benghazi, Libya. The total sample was 381 patients: T1DM 15 (n), and T2DM 366 (n). T1DM was excluded from our results. Patients with T2DM were divided into two groups: the control group (not on metformin) consisted of 71 patients, and the group that received metformin (M group) consisted of 295 patients.
Aims of the Study
To assess serum vitamin B12 levels in patients with T2DM and evaluate the prevalence of vitamin B12 deficiency among those receiving metformin treatment.
Results
The M group significantly decreased vitamin B12 serum levels by 443.56 mg/mL versus the control group of 541.33 pg/mL (p = 0.003). The prevalence of patients with vitamin B12 deficiency under the metformin treatment was 23.84%. There was no significant difference in correlation between serum vitamin B12 levels and both doses of metformin and the duration of diabetes mellitus.
Conclusion
Vitamin B12 was significantly decreased in patients with T2DM receiving metformin.